Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with NarcolepsyMay 2, 2023
Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart HealthMarch 30, 2023
NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience® (Mazindol ER) in the Treatment of NarcolepsyNovember 22, 2022
Webinar with Dr. Gary Zammit, President and CEO of Clinilabs Drug Development CorporationOctober 28, 2022
